Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Johnson & Johnson

Next Previous
X
Search
Drug Profile

Abiraterone acetate - Johnson & Johnson

Alternative Names: Abirateron-acetate-fine-particles; Aviraterone acetate; CB-7630; JNJ-212082; Zaitiga; Zaytiga; Zitiga; Zytiga

Latest Information Update: 03 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Assistance Publique Hopitaux de Paris; Cancer Research UK; Cougar Biotechnology; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • No development reported Congenital adrenal hyperplasia

Most Recent Events

  • 03 Jan 2024 No development reported - Phase-III for Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease) in Italy (PO) (NCT02257736) (EudraCT2014-001718-25)
  • 02 Jun 2023 Updated efficacy data from the phase III PEACE-1 trial in in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 31 Dec 2022 Canadian Court dismisses lawsuit type filed against Dr. Reddy’s Laboratories by Janssen for filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (’422) in Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top